Figure 1.
Seliciclib treatment decreases viability of MM cells in a dose-dependent manner. The effect of seliciclib on viability of MM cells was determined by MTT assays. MM cell lines sensitive (MM.1S, OPM2, RPMI, U266) and resistant (Dox-40, LR5, MM1.R) to conventional therapies, as well as patient MM cells, were cultured in the presence of increasing doses of seliciclib (0-100 μM) for 24 hours. Seliciclib resulted in dose-dependent cytotoxicity, with an IC50 ranging from 15 to 25 μM at 24 hours.
